share_log

RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $28 Price Target

Moomoo 24/7 ·  Mar 12 11:12

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $28 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment